�Samprada & Nanhamati Singh Family Trust has submitted to exchange a copy of Disclosure with respect to Samprada and Nanhamati Singh Family Trust.
ALKEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.7 pts more than Nifty Midcap 150 and 0.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Samprada & Nanhamati Singh Family Trust, part of the promoter group of Alkem Laboratories, sold 0.67% of the company's shares on June 11, 2025. Following this sale, the Trust's holding in Alkem has reduced from 19.41% to 18.74%. The proceeds from the sale were distributed to the beneficiaries of the Trust. The disclosure is being made under a SEBI exemption order dated March 10, 2017, which requires the Trust to report any changes in its shareholding. The Trust continues to remain a significant shareholder in the company post the transaction.
This is a small reduction (less than 1%) in promoter group holding and is unlikely to materially affect the stock price. However, it indicates some monetisation by promoter-related entities, which retail investors may monitor for further reductions.